Role of CYP3A5 in abnormal clearance of methadone

Annals of Pharmacotherapy

Volumn 42, Issue 6, 2008, Pages 893-897

  De Fazio, Salvatore ^a   Gallelli, Luca ^a,b   De Siena, Antonella ^c   De Sarro, Giovambattista ^b   Scordo, Maria Gabriella ^d  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Donnelly Corporation   (United States)

^c ASL 8   (Italy)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

CYP2C19; CYP3A5; Methadone; P glycoprotein gene; Polydrug abuser

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; CYTOCHROME P450; CYTOCHROME P450 3A5; GLYCOPROTEIN P; METHADONE;

ADULT; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; GENE FREQUENCY; HUMAN; MAINTENANCE THERAPY; MALE; MULTIPLE DRUG ABUSE; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; URINALYSIS; WITHDRAWAL SYNDROME;

EID: 44649191849     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K539     Document Type: Article

References (43)

1. Farrell M, Ward J, Mattick R, et al. Methadone maintenance treatment in opiate dependence: a review. BMJ 1994;309:997-1001.
2. Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone - metabolism, pharmacokinetics and interactions. Pharmacol Res 2004;50:551-9.
3. Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999;47:403-12.
4. Kristensen K, Blemmer T, Angelo HR, et al. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 1996;18:221-7.
5. Leshner AI. Drug abuse and addiction treatment research: the next generation. Arch Gen Psychiatry 1997;54:691-4.
6. Sullivan HR, Due SL. Urinary metabolites of dl-methadone in maintenance subjects. J Med Chem 1973;16:909-13.
7. Loimer N, Schmid R. The use of plasma levels to optimize methadone maintenance treatment. Drug Alcohol Depend 1992;30:241-6.
8. de Vos JW, Geerlings PJ, van den Brink W, Ufkes JG, van Wilgenburg H. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 1995;48:361-6.
9. Boulton DW, Devane CL. Development and application of a chiral high performance liquid chromatography assay for pharmacokinetic studies of methadone. Chirality 2000;12:681-7.
10. Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-7.
11. Hersberger M, Marti-Jaun J, Rentsch K, Henseler E. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 2000; 46:1072-7.
12. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolism of debrisoquine. Characterisation and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996;392:30-4.
13. Steijns LS, Van Der Weide J. Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem 1998;44:914-7.
14. van Schaik RNH, de Wildt SN, van Iperen NM, Uitterlinden AG, van der Anker JN, Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 2000;46:1834-6.
15. van Schaik RNH, de Wildt SN, Brosen R, van Fessen M, van der Anker JN, Lindemans J. The CYP3A4*3 allele: is it really rare? Clin Chem 2001;47:1104-6.
16. Wang A, Yu B-N, Luo C-H, et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of symvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 2005;60:843-8.
17. van Schaik RNH, van der Heiden IP, van der Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002;48:1668-71.
18. Mirghani RA, Sayi J, Aklillu E, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity compared to a Swedish population. Pharmacogenet Genomics 2006;16:637-45.
19. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
20. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76:250-69.
21. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004;16: 36-44.
22. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 2007;321:389-99.
23. Wu D, Otton SV, Sproule BA, et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993;35:30-4.
24. Rook EJ, Hillebrand MJ, Rosing H, van Ree JM, Beijnen JH. The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;824:213-21.
25. Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-73.
26. Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 2001;298: 1021-32.
27. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 2004;26:192-9.
28. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat Genet 2001;27:383-91.
29. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-9.
30. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
31. Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174:1715-22.
32. Meur YL, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006;80:51-60.
33. Utecht KN, Hiles JJ, Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm 2006;63:2340-8.
34. Crettol S, Déglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005;78:593-604.
35. Nanovskaya T, Nekhayeva I, Karunaratne N, Audus K, Hankins GD, Ahmed MS. Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol 2005;69:1869-78.
36. Rodriguez M, Ortega I, Soengas I, Suarez E, Lukas JC, Calvo R. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. J Pharm Pharmacol 2004;56:367-74.
37. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33.
38. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004;25:423-9.
39. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006;80:682-90.
40. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006;80:668-81.
41. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistant gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8.
42. Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 2004; 57:600-10.
43. Ozawa S, Soyama A, Saeki M, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004;19:83-95.